Quantification of brain-derived extracellular vesicles in plasma as a biomarker to diagnose Parkinson's and related diseases

There is still a substantial unmet need for blood-based biomarkers to make an objective diagnosis of Parkinson's disease (PD) and the parkinsonism-plus syndromes. This study is aimed to determine whether enumeration of brain-derived exosomes (BDEs) in plasma is informative in the diagnosis of t...

Full description

Saved in:
Bibliographic Details
Published in:Parkinsonism & related disorders 2019-04, Vol.61, p.82-87
Main Authors: Ohmichi, Takuma, Mitsuhashi, Masato, Tatebe, Harutsugu, Kasai, Takashi, Ali El-Agnaf, Omar M., Tokuda, Takahiko
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Astrocyte-derived exosome
Astrocytes - metabolism
Biomarkers - metabolism
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Excitatory Amino Acid Transporter 1 - metabolism
Exosomes - metabolism
Extracellular Vesicles - metabolism
Female
GPI-Linked Proteins - metabolism
Humans
Male
Middle Aged
Multiple System Atrophy - metabolism
Myelin Proteins - metabolism
Neuron-derived exosome
Neurons - metabolism
Oligodendrocyte-derived exosome
Oligodendroglia - metabolism
Parkinson Disease - metabolism
Parkinson's and related diseases
Plasma biomarker
Supranuclear Palsy, Progressive - metabolism
Synaptosomal-Associated Protein 25 - metabolism
Tetraspanin 28
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is still a substantial unmet need for blood-based biomarkers to make an objective diagnosis of Parkinson's disease (PD) and the parkinsonism-plus syndromes. This study is aimed to determine whether enumeration of brain-derived exosomes (BDEs) in plasma is informative in the diagnosis of those diseases. We have developed a specific method to enumerate the plasma levels of neuron-derived, astrocyte-derived, and oligodendrocyte-derived exosomes (NDEs, ADEs and ODEs, respectively), and quantified them individually in patients with PD (n = 15), multiple system atrophy (MSA, n = 15), progressive supranuclear palsy (PSP, n = 7) and disease controls (n = 15). Our assays employ specific antibodies against molecules expressed by neurons, astrocytes and oligodendrocytes, respectively, combined with an antibody to the exosome common marker CD81. The plasma levels of NDEs showed significant increase in PD compared to control (p 
ISSN:1353-8020
1873-5126
DOI:10.1016/j.parkreldis.2018.11.021